Evgen Pharma joined the AIM market of the London Stock Exchange in October 2015 and subsequently acquired the world-wide rights to a series of novel sulforaphane analogues from the Spanish Research Council and the University of Seville.
In March 2019, Evgen Pharma announced positive results from the open-label Phase II trial of SFX-01 in patients with oestrogen-positive metastatic breast cancer that had become resistant to all prior lines of hormone therapy.
In September 2020 Evgen announced a licence agreement with Juvenescence for SFX-01 in non-pharmaceutical applications for high-end nutritional health products. JuvLife is a US-based company developing IP-protected dietary products and functional foods to support consumers as they manage their health and affect the onset of age-related conditions.
Evgen’s Board is led by Barry Clare and the company welcomed Richard Moulson as Chief Financial Officer in January 2017. Dr Huw Jones joined Evgen in October 2020 as Chief Executive Officer.